The fact is, no one is truly safe until everyone is safe.

The mRNA UCV Consortium is formed for development and delivery of the mRNA Universal Coronavirus Vaccine.

NORVAX Limited founded the mRNA UCV Consortium with the mission to develop and manufacture the mRNA Universal Coronavirus Vaccine (UCV) at industrial scale for COVAX Markets and HIC Markets for delivery in 2022/23 on Advance Purchase Agreements (APA) by sponsors, governments and industry customers. The vision of mRNA UCV Consortium is to help end the COVID-19 pandemic and to stimulate and support pandemic preparedness for future outbreaks.

The goal of the mRNA UCV in development by Norvax with the mRNA UCV Consortium is to help solve the urgent global need for a one-time COVID-19 booster to save lives and help to end the COVID-19 pandemic and to support mRNA vaccine innovation for therapeutics and cancers.

mRNA UCV Consortium Map

Mmbers of the mRNA UCV Consortium

NORVAX Limited is the product developer and is leading the organization of the consortium and is the Secretariat for Vaxcomm the Vaccine Commons. NORVAX was founded by Peter A. Jensen, and is located in London, England. Mr. Jensen has 35+ years of biotech and business innovation in UK and US. Mr. Jensen is the founder of Vaxcomm the Vaccine Commons.

UKvax Factory focus for 2021 is rapid long-term growth, achieved through short- and long-term pandemic strategies. Our GMP manufacturing solution will support the current COVID-19 pandemic with industrial scale infrastructure. We plan to deliver sustained pandemic preparedness through open science research and development in The UK, Scandinavia and the EU. As a social enterprise our goal is to provide affordable solutions to deliver high impact for global public health.

Visit Website

UKvax Factory focus for 2021 is rapid long-term growth, achieved through short- and long-term pandemic strategies. Our GMP manufacturing solution will support the current COVID-19 pandemic with industrial scale infrastructure. We plan to deliver sustained pandemic preparedness through open science research and development in The UK, Scandinavia and the EU. As a social enterprise our goal is to provide affordable solutions to deliver high impact for global public health.

Visit Website

AmpTec (Merck) – Strategic mRNA Technology Partner, with Merck. TEAM-1 Member.
AmpTec is a leading international provider of RNA technology products, including RNA isolation and mRNA amplification kits, synthetic long RNAs and DNAs as well as functional mRNAs. We are committed to direct and flexible customer interactions with life science industries and academic research institutions around the world, including on-site technical support including: (1) High Quality Provider of IVT-RNAs since 1998, (2) Provider of synthetic Nucleic Acids for worldwide leading Companies in the field of molecular diagnostics and biotechnology, (3) Manufacturer in compliance with ISO 9001 since 2008, (4) Manufacturer in compliance with ISO 13485 since 2010. (5) Compliance with cGMP since 2012 (regulations of FDA 21 CFR Part 820), (6) Implementation of cGMP FDA 21 CFR Part 211 and ICH Q7 (section 19: APIs for use in clinical trials) requirements in advanced state (7) quality management system, certified by DQS MED. AmpTec has been acquired by Merck, a leading science and technology company, based in Germany.

Visit Website

Bausch+Ströbel is a trusted and experienced supplier to the pharmaceutical industry specializing in filling and packaging systems. B+S filling and packaging lines are used worldwide to fill syringes, vials, cartridges and ampoules with high-grade liquid and powder pharmaceutical products. Applications range from cleaning and sterilization to labelling and syringe assembly. In addition to designing and building systems tailored to customer specifications, Bausch+Ströbel provide a wide range of specialized services aimed at ensuring system reliability and productivity.

Visit Website

Berkeley Communcations is an international full-service PR and communications agency, aiming to bring the power of the story in every business they work work with.

Visit Website

Strategic mRNA GMP Upstream/Downstream Technology Vendor: CYTIVA (subcontract; GMP Design consultant, GMP Systems) Advancing the development and manufacture of therapeutics. Cytiva is a global provider of technologies and services that advance and accelerate the development and manufacture of therapeutics. We have a rich heritage tracing back hundreds of years, and a fresh beginning since 2020. Our customers undertake life-saving activities ranging from fundamental biological research to developing innovative vaccines, biologic drugs, and novel cell and gene therapies. Our job is to supply the tools and services they need to work better, faster and safer, leading to better patient outcomes. Cytiva is a global life sciences leader with over 7,000 associates across 40 sites who are dedicated to our vision to improve access to life-changing therapies that transform human health. As a trusted partner to customers that range in scale and scope, Cytiva brings efficiencies to research and manufacturing workflows, ensuring the development, manufacture and delivery of transformative medicines to patients. We operate in 40 countries and territories covering Europe, Asia, North and Latin America, and the Middle East. Our 7,000 associates are dedicated to our mission to advance and accelerate therapeutics. We host 11 customer-centered innovation facilities across Asia, Europe and the Americas to carry ideas through to commercial development.

Visit Website

Codex DNA empowers researchers with end-to-end solutions and tools they need to rapidly and securely design, code, and create synthetic DNA. Experience up to 20x increases in productivity to your product development cycles. Creators of the BioXp™ system — the world’s only synthetic biology workstation — and the industry-standard Gibson Assembly® method, provide comprehensive end-to-end solutions across your synthetic biology workflows, Codex DNA, Inc. is accelerating advances in the fields of personalized medicine, biologics drug discovery, vaccine development, genome editing, and cell and gene therapy.

Visit Website

ECAM Biomed Global Impact Limited. FCA Reference number: 926731 Peter Albert Jensen. FCA approved person. CF1 Director (AR). CF30 Customer. Individual Reference Number: PXJ84051. eCAM Biomed Global Impact Limited is an Appointed Representative of Robert Quinn Advisory LLP, which is authorised and regulated by the Financial Conduct Authority. eCAM Biomed Global Impact Limited is incorporated in England and the registered office is at 219 Kensington High Street, London, W8 6BD, UK. The investment products and services of eCAM Biomed Global Impact Limited are only available to professional clients and eligible counterparties- NOT available to retail clients.

Visit Website

eTheRNA – Strategic mRNA Technology Partner for this application. TEAM-1 Member.
eTheRNA. Advanced Technology Boosting Immunotherapy. eTheRNA immunotherapies is developing first in class mRNA immunotherapies for the treatment of cancer and infectious diseases. We employ messenger RNA to unleash and boost a patient’s immune response against a tumor or infectious agent. Research shows that this approach results in long lasting clinical remission in cancer patients and protective immunity against infections. eTheRNA was established in January 2013 as a spin-off company from the ‘Vrije Universiteit Brussel’ (VUB), following the development of its TriMix mRNA technology. Key Milestones. 2015 -2018. (i) Spun out of Vrije Universiteit Brussel, a prominent university in the capital of Belgium, (ii) Establish core TriMix mRNA platform, (iii) Translational Phase I/II clinical studies. 2019 – 2021. (iv) GMP facility established, (v) Novel formulation, (vi) Establish product pipeline, (vii) Asia expansion. For the convenience of patients and practitioners, eTheRNA is working on an mRNA-formulation that can be administered needle-free, via intranasal administration.

Visit Website

IQVIA – Strategic Clinical Research Organization (CRO) Partner – Contractual
IQVIA. Driving healthcare forward. IQVIA is a world leader in using data, technology, advanced analytics, and expertise to help customers drive healthcare forward. Together with the companies we serve, we are enabling a more modern and effective healthcare system and creating breakthrough solutions that transform business and patient outcomes. IQVIA capabilities and expertise: (i) 1+ Billion Patient Identified Records, (ii) 72x faster data analytics using IQVIA human data science cloud, (iii) 40+ offerings; commercial offerings using artificial intelligence and machine based learning, (iv) 70,000 experts from clinicians to data scientists, serving customers in 100+ countries. In 2016, Quintiles and IMS Health came together to create something entirely new. IQVIA brings together advances in data science, technology, and human science expertise to help the healthcare industry make better decisions, and ultimately to improve patient outcomes. This vision for a healthier world, and the work we do to help the industry move forward, is why IQVIA is The Human Data Science Company™.

Visit Website

HIC-Vac is an international network of researchers who are developing human infection challenge (HIC) studies to accelerate the development of vaccines against pathogens of high global impact.

By bringing together the brightest minds in the field, we want to speed up vaccine development and reduce the burden of some of the world’s most crippling diseases by supporting human infection studies. Our goal is to foster an engaged and interactive community of international researchers to promote open sharing of knowledge and expertise, generate new ideas, support and share best practice, and form new cross-discipline collaborations.

Our Network will support this vision by providing catalyst funding – pump-priming grants to develop early stage research ideas, and grants to enable researchers to advance their career development through training opportunities.

Visit Website

Merck KGaA – Strategic Technology Vendor. Lipid Catalog. DNA/RNA Upstream/Downstream Systems
Dedicated to human progress. Our purpose is to solve the toughest challenges in the life science industry in collaboration with the global scientific community. With our Research Solutions, Process Solutions, and Applied Solutions business units, we are a leading worldwide supplier of tools, high-grade chemicals, and equipment for academic labs, biotech, and biopharmaceutical manufacturers, as well as the industrial sector. Research Solutions provides our academic customers with the chemicals and biological tools needed to make scientific discovery easier and faster. Process Solutions provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing. Applied Solutions offers analytical workflows and both lab connectivity and digitization solutions to empower the labs of the future. Our passion for science and technology is what drives our 58,000 employees in 66 countries to find solutions to some of today’s toughest challenges and create more sustainable ways to live.

Visit Website

NEC OncoImmunity – Strategic Technology Service Partner. TEAM-1 Member.
NEC OncoImmunity AS is a bioinformatics company offering proprietary machine-learning based software to address the key knowledge gaps in the prediction of bona fide immunogenic neoantigens for personalized cancer immunotherapy. NEC OncoImmunity AS is dedicated to develop software solutions that facilitate effective patient selection for cancer immunotherapy, and identify optimal neoantigen targets for truly personalised cancer vaccines & cell therapies in a clinically actionable time-frame. NEC OncoImmunity AS offers software solutions powered by a machine-learning engine that predicts from next generation sequencing data, true neoantigens for personalized cancer immunotherapy and cancer immunotherapy biomarkers, and for SARS-CoV-2.18 NEC OncoImmunity AS is a subsidiary of NEC Corporation, and is based in Oslo, Norway.

Visit Website

Norsk Regnesentral – Strategic R&D Partner. TEAM-1 Member.
Norsk Regnesentral (NR, Norwegian Computing Center) is a private, non-profit, independent research institute that carries out contract research in the areas of computer science, applied statistics and machine learning for a broad range of industrial, commercial, and public organisations in Norway, as well as internationally. It is Norway’s leading applied statistical institute and one of Europe’s largest non-university centres in this area. We have 85 researchers, and 70 of these works within the fields of statistical modelling, machine learning, deep learning and image analysis. Our main applications are finance and insurance, earth observation, climate and environment, health, management, image analysis and petroleum. Our work within health includes bioinformatics, cancer research, clinical trials (including vaccine trials), medical image analysis and infectious diseases in humans and in fish.

Visit Website

Syntegon – Strategic Technology Vendor. Contractual (PO in process)
Syntegon is a leading provider of processing and packaging technology. As a highly trusted partner to the food and pharmaceutical industries we supply customers with intelligent and sustainable solutions worldwide. As the former Bosch Packaging Technology GmbH headquartered in Waiblingen (Germany) we supply a wide range of machinery, systems, and services. 6,000 associates at more than 30 locations in over 15 countries, provide industry-specific consulting, engineering expertise, and machinery services. The FLC 3000 is a reliable and pioneering solution for the safe, efficient filling and closing of vials and infusion bottles in pharmaceutical production. Pharmaceutical manufacturers all over the world appreciate its unique combination of flexibility and compact design as well as the large variety of different equipment. With its impressive processing range with filling volumes from 0.5 to 500ml, the FLC fulfills the demands of modern everyday production. The large range of filling volumes is achieved by only three sets of size parts with minimal changeover times. The FLC is equipped with a continuous transport system, providing the best conditions for a robust and gentle vial or bottle process. Servo controlled programs guarantee the necessary precision and reproducibility of motion sequences. The FLC sets standards for operator convenience and ergonomics. The entire machine can be operated from one side. Size parts can be changed without the usage of tools. With more than 450 installed machines the FLC is the best sold pharmaceutical filling and closing machine ever.

Visit Website

The VALIDATE Network
Vaccine development for complex intracellular neglected pathogens. VALIDATE is an international network of researchers developing vaccines against globally significant diseases caused by complex intracellular pathogens. Our initial focus is on tuberculosis (TB), leishmaniasis, melioidosis, and leprosy, which cause substantial mortality and morbidity across the globe, particularly in low and middle-income countries (LMICs). By working together, we will advance research more quickly and effectively.

Visit Website

The Vaccine Confidence Project™ (VCP) has spent the last ten years tackling these issues. Through the Vaccine Confidence Index™ (VCI), a tool for mapping confidence, we help to inform the strategies and designs for immunization programmes so human and financial resources can be designed for and with the communities they serve. The VCP began by developing a system for early detection of public concerns about vaccines. Through it, the VCP collects data and applies a diagnostic tool to determine the risk level as to whether those concerns could disrupt vaccine programmes and uptake. Our insights guide when and how to respond, offering an opportunity to build and sustain confidence in vaccines and immunization.

Visit Website

Vaxcomm
Vaxcomm is The Vaccine Commons for affordable access to modern vaccine technologies for the benefit of members and of the global public health commons. Vaxcomm is open to all members who support and engage the Vaxcomm commons principles and rules of the community.
Design principles for Common Pool Resource (CPR) institution. Ostrom identified eight “design principles” of stable local common pool resource management:

  1. Clearly defined (clear definition of the contents of the common pool resource and effective exclusion of external un-entitled parties)
  2. The appropriation and provision of common resources that are adapted to local conditions;
  3. Collective-choice arrangements that allow most resource appropriators to participate in the decision-making process;
  4. Effective monitoring by monitors who are part of or accountable to the appropriators;
  5. A scale of graduated sanctions for resource appropriators who violate community rules;
  6. Mechanisms of conflict resolution that are cheap and of easy access;
  7. Self-determination of the community recognized by higher-level authorities;
  8. In the case of larger common-pool resources, organization in the form of multiple layers of nested enterprises, with small local CPRs at the base level.
Visit Website

Vaccinopolis by The University of Antwerp

A unique centre of excellence for vaccination studies.

Vision; Accelerate the evaluation of vaccine candidates, Participate in global efforts for better epidemic preparedness. Values; Build a unique clinical infrastructure, Support a global network and internationalization. Mission; Ensuring maximal participant safety and security, Flexibility to perform almost any vaccine trial. Unique 6000m² clinical facility. 30 bed quarantine unit (BSL 3 level). Ambulatory vaccine trial unit. Fully equipped BSL 2 and BSL 3 labs. 500m from university hospital. Located at University of Antwerp. Strategic location in Belgium with easy connection to Antwerp and Brussels.

Visit Website

Waystone leads the way in specialist services for the asset management industry.

Partnering institutional investors, investment funds and asset managers, Waystone builds, supports and protects investment structures and strategies worldwide. With over 20 years’ experience and a comprehensive range of specialist services to its name, Waystone is now serving assets under management in excess of $1Tn.

Waystone provides its clients with the guidance and tools to allow them to focus on managing their investment goals with confidence.

Visit Website

Watson-Marlow Fluid Technology Group (WMFTG) is the world leader in niche peristaltic pumps and associated fluid path technologies for the food, pharmaceutical, chemical and environmental industries. Comprising ten established brands, each with their area of expertise, but together offering our customers unrivalled solutions for their pumping and fluid transfer applications.

Customers demand many things from their process equipment and the prime concern is maintaining product integrity. Positive displacement pump companies such as Watson-Marlow Fluid Technology Group (WMFTG) need to supply products which meet a range of requirements including value for money; low cost of ownership; reliability; ease of maintenance; and proven after-sales service.

Visit Website

We develop creative, comprehensive and sustainable engineering solutions for a future where society can thrive. Equipped with an intimate understanding of local intricacies, world-class talent and proactive leadership, we plan, design, manage and engineer long lasting and impactful solutions to uniquely complex problems.

Visit Website